[EN] 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE LA RATE (SYK) CONTENANT UN 2-PYRIDYL CARBOXAMIDE
申请人:MERCK SHARP & DOHME
公开号:WO2013052394A1
公开(公告)日:2013-04-11
The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
Compounds useful as reversible inhibitors of cysteine proteases
申请人:——
公开号:US20020058809A1
公开(公告)日:2002-05-16
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
1
[EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
申请人:AXYS PHARMACEUTICALS
公开号:WO2004108661A1
公开(公告)日:2004-12-16
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Method of inducing antiandrogenic activity using imidazolidines
申请人:Roussel Uclaf
公开号:US05646172A1
公开(公告)日:1997-07-08
Novel imidazoles of the formula ##STR1## wherein the substituents are as defined in the disclosure and their non-toxic, pharmaceutically acceptable addition salts with acids and bases having antiandrogenic activity.
Cyanomethyl derivatives as cysteine protease inhibitors
申请人:Graupe Michael
公开号:US20060122184A1
公开(公告)日:2006-06-08
The present invention is directed to cyanomethyl derivatives that are inhibitors of cysteine protease, in particular, cathepsin B, K, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.